UBS Group AG Buys 55,924 Shares of Aurinia Pharmaceuticals Inc $AUPH

Posted by Brenda Bartman on May 23rd, 2026

UBS Group AG boosted its stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Free Report) (TSE:AUP) by 28.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 254,672 shares of the biotechnology company’s stock after acquiring an additional 55,924 shares during the quarter. UBS Group AG’s holdings in Aurinia Pharmaceuticals were worth $4,062,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Arrowstreet Capital Limited Partnership lifted its position in Aurinia Pharmaceuticals by 213.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,374,021 shares of the biotechnology company’s stock valued at $37,283,000 after purchasing an additional 2,297,903 shares during the period. Marshall Wace LLP lifted its position in Aurinia Pharmaceuticals by 1,272.5% during the 3rd quarter. Marshall Wace LLP now owns 1,483,132 shares of the biotechnology company’s stock valued at $16,389,000 after purchasing an additional 1,375,072 shares during the period. Two Sigma Investments LP lifted its position in Aurinia Pharmaceuticals by 728.6% during the 3rd quarter. Two Sigma Investments LP now owns 1,341,067 shares of the biotechnology company’s stock valued at $14,819,000 after purchasing an additional 1,179,219 shares during the period. Jacobs Levy Equity Management Inc. lifted its position in Aurinia Pharmaceuticals by 63.0% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,219,451 shares of the biotechnology company’s stock valued at $13,475,000 after purchasing an additional 471,338 shares during the period. Finally, BNP Paribas Financial Markets lifted its position in Aurinia Pharmaceuticals by 3,132.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 421,358 shares of the biotechnology company’s stock valued at $4,656,000 after purchasing an additional 408,324 shares during the period. Institutional investors own 36.83% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, May 15th. Two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Aurinia Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $17.25.

Get Our Latest Analysis on Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Stock Performance

Aurinia Pharmaceuticals stock opened at $15.22 on Friday. The company has a current ratio of 5.55, a quick ratio of 5.01 and a debt-to-equity ratio of 0.08. Aurinia Pharmaceuticals Inc has a 1 year low of $7.28 and a 1 year high of $16.88. The company has a market cap of $1.96 billion, a PE ratio of 7.01 and a beta of 1.44. The company’s 50-day moving average is $15.38 and its two-hundred day moving average is $15.21.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last released its earnings results on Thursday, May 7th. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.07. Aurinia Pharmaceuticals had a net margin of 99.97% and a return on equity of 26.62%. The company had revenue of $77.71 million for the quarter, compared to the consensus estimate of $76.98 million. Equities analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.82 earnings per share for the current year.

Insider Transactions at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Kevin Tang bought 516,439 shares of the business’s stock in a transaction on Friday, February 27th. The shares were bought at an average cost of $13.99 per share, for a total transaction of $7,224,981.61. Following the transaction, the director owned 11,845,939 shares in the company, valued at approximately $165,724,686.61. This trade represents a 4.56% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 12.20% of the company’s stock.

Aurinia Pharmaceuticals Profile

(Free Report)

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.